Bayer Schering Pharma Ag

Orion Corporation

Delsitech Oy

Bayer Oy

Pirjo Kortesuo

Ilkka Jutila

Ulla Calvo Alonso

Harri Jukarainen

Hannu Nikander

Pirjo Sallinen

Eeva Lukkari-Lax

Joachim Moede

Juha Lehtinen

Pirjo Inki

David Whitaker

Andrew Macleod

Michael Nobel

Juha Kiesvaara

Manja Ahola

Kaija Af Ursin

Jukka Salmia

Heikki Niskanen

Mikko Kananen

Antti Yli-Urpo

Ilkka Kangasniemi

Kauko Kurkela

Heidi Fagerholm

Niilo Saarinen

Christian Wamprecht

Heikki Lyytikäinen

Taina Tjäder

Wolfgang Kaufhold

Mika Jokinen

Timo Peltola

Leena Otsomaa

Faisal Shafiq

Sinikka Veittola

Gunilla Örn

Gunilla &Ouml;rn

The present invention relates to novel intrauterine systems and to methods for manufacturing these systems. An intrauterine system according to the invention comprises a reservoir and a continuous, closed and flexible frame. The frame comprises a thermoplastic polyurethane elastomer made of a polycarbonate diol, 1,6-hexamethylenediisocyanate, and a chain extender.

Intrauterine system

A method for preparing controllably biodegradable silica fibres which includes spinning the fibres from a silica sol of controlled viscosity, controllably biodegradable silica fibres prepared according to the method, methods for controlling the biodegradability of the fibres, the use of controllably biodegradable fibres as sustained and/or controlled release delivery devices for biologically active agents, and pharmaceutical preparations containing such devices.

Biodegradable ceramic fibres from silica sols

Intrauterine device

Controllably dissolvable silica-xerogels prepared via sol-gel process and their use. A delivery device including controllably dissolvable silica-xerogel into which structure a biologically active agent is incorporated. Pharmaceutical preparations including this device. Medical devices for orthopedic and surgical purposes which contain controllably dissolvable silica-xerogels, which may further include a biologically active agent.

Dissolvable oxides for biological applications

Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further contain 1-4 hydroxyl, 1-3 oxo, or one or several halogen substituents, or a corresponding anion thereof, or methanesulfonic acid or its corresponding anion, in molar excess with respect to the triphenylethylene antiestrogen, optionally together with an organic water miscible co-solvent such as polyethylene glycol (PEG), propylene glycol, ethanol or isopropanol.

Soluble compositions of triphenylethylene antiestrogens

Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid having 1-5 carbon atoms, wherein the carbon chain may further contain 1-4 hydroxyl, 1-3 oxo, or one or several halogen a substituents, or a corresponding anion thereof, or methanesulfonic acid or its corresponding anion, in molar excess with respect to the triphenylethylene antiestrogen, optionally together with an organic water miscible co-solvent such as polyethylene glycol (PEG), propylene glycol, ethanol or isopropanol.

Aqueous compositions of toremifene or a pharmaceutically acceptable salt thereof, comprising lactic acid, acetic acid, formic acid, methanesulfonic acid or the corresponding anion (lactate, acetate, formate or mesylate) as a solubility enhancing agent. Novel salts of toremifene with an acid selected from the group consisting of lactic acid, acetic acid, formic acid or methanesulfonic acid.

Soluble compositions of toremifene

Growing community of inventors

Parainen, Finland

Pirjo Kortesuo